Dispensing patterns of prescription-only antiobesity preparations in South Africa

References

• Kim GW, Lin JE, Biomain ES, et al. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2014 Jan;95(1):53–66.
   PubMed Web of Science ®Google Scholar
• Sartorius B, Veerman LJ, Manyema M, et al. Determinants of obesity and associated population attributability, South Africa: empirical evidence from a national panel survey, 2008-2012. Zeeb H, editor. PLOS ONE. 2015;10(6):e0130218.10.1371/journal.pone.0130218
   PubMed Web of Science ®Google Scholar
• Kushner RF. Weight loss strategies for treatment of obesity. Prog Cardiovasc Dis. 2014 Jan–Feb;56(4):465–72.10.1016/j.pcad.2013.09.005
   PubMed Web of Science ®Google Scholar
• Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nat Rev Endocrin. 2013;9:13–27.
   PubMed Web of Science ®Google Scholar
• Wang YC, McPherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378:815–25.10.1016/S0140-6736(11)60814-3
   PubMed Web of Science ®Google Scholar
• Ng M, Fleming T, Robinson M., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2015;384(9945):766–81.
   Web of Science ®Google Scholar
• Micklesfield LK, Lambert EV, Hume DJ, et al. Socio-cultural, environmental and behavioural determinants of obesity in black South African women. Cardiovasc J Afr. 2013;24:1–7.
   Web of Science ®Google Scholar
• Adeboye B, Bermano G, Rolland C. Obesity and its health impact in Africa: a systematic review. Cardiovasc J Afr. 2012 Oct;23(9):512–21.10.5830/CVJA-2012-040
   PubMed Web of Science ®Google Scholar
• Alaba OA, Chola L. Prevalence of age-adjusted obesity in South Africa and the influence of social determinants: an ecological analysis. Lancet. 2013;381:S6.10.1016/S0140-6736(13)61260-X
   Google Scholar
• Truter I. Prescription appetite suppressants: a drug utilisation study using a claims database. JAPS. 2014 Aug;4(8):32–5.
   Google Scholar
• Rossiter D, editor. South African Medicines Formulary (SAMF). 11th ed. Cape Town: Health and Medical Publishing Group of the South African Medical Association; 2014.
   Google Scholar
• South African Pharmacy Council. Statistics for registered persons and organisations [homepage on the Internet]. 2015. c2015. Available from: http://www.pharmcouncil.co.za/B_Statistics.asp.
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2015 [homepage on the Internet]. Oslo. 2015. c2015. Available from: http://www.whocc.no/atc_ddd_index/.
   Google Scholar
• Snyman J, editor. MIMS Monthly Index of Medical Specialities (MIMS). Saxonwold: MIMS. 2011;51(6).
   Google Scholar
• ICD-10 Version: 2016. ICD-10 - World Health Organization. 2015. c2015. Available from: http://apps.who.int/classifications/icd10/browse/2016/en.
   Google Scholar
• Patterson L, Kee F, Hughes C, et al. The relationship between BMI and the prescription of antiobesity medication according to social factors: a population cross sectional study. BMC Public Health. 2014;14:815.10.1186/1471-2458-14-87
   Web of Science ®Google Scholar
• McGill A-T. Past and future corollaries of theories on causes of metabolic syndrome and obesity related co-morbidities part 2: a composite unifying theory review of human-specific co-adaptations to brain energy consumption. Arch Pub Health. 2014;72:30.10.1186/2049-3258-72-31
   Google Scholar
• Pugh R. New E: obesity drug phentermine is not addictive 20th European congress on obesity. Abstract T5:OS2.3, presented May 15, 2013. Obes Facts. 2013;6:22–48.
   Google Scholar
• Fleming JW, McClendon KS, Riche DM. New obesity agents: lorcaserin and phentermine/topiramate. Ann Pharmacother. 2013;47:1007–16.10.1345/aph.1R779
   PubMed Web of Science ®Google Scholar
• Rodgers RJ, Tschop MH, Wilding JPH. Antiobesity drugs: past, present and future. Dis Model Mech. 2012;5(5):621–6.10.1242/dmm.009621
   PubMed Web of Science ®Google Scholar
• Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacother. 2013 Dec;33(12):1299–307.10.1002/phar.1342
   PubMed Web of Science ®Google Scholar
• Finkelstein EA, Kruger E, Karnawat S. Cost-Effectiveness Analysis of Qsymia for Weight Loss. PharmacoEconomics 2015 Jul;33(7):699–706.10.1007/s40273-014-0182-6
   PubMed Web of Science ®Google Scholar
• Boland CL, Harris JB, Harris KB. Pharmacological management of obesity in pediatric patients. Ann Pharmacother. 2015 Feb;49(2):220–32.10.1177/1060028014557859
   Web of Science ®Google Scholar
• Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity. JAMA. 2014;311(1):74–86.10.1001/jama.2013.281361
   PubMed Web of Science ®Google Scholar